🔥🐔 BizChicken 🐔🔥
Companies Similar to Fulcrum Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
Fulcrum Therapeutics, Inc.
losmapimod and FTX-6058
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.
Symbol: FULC
Recent Price: $4.68
Industry: Biotechnology
CEO: Mr. Alexander C. Sapir
Sector: Healthcare
Employees: 76
Address: 26 Landsdowne Street, Cambridge, MA 02139
Phone: 617 651 8851
Last updated: 2024-12-31
Lexicon Pharmaceuticals, Inc.
Sotagliflozin, LX9211
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products, with drugs like Sotagliflozin and LX9211 under development for heart failure, type 1 diabetes, and neuropathic pain.
About | Foundation | Leadership | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: LXRX
Recent Price: $0.72
Industry: Biotechnology
CEO: Dr. Michael Exton Ph.D.
Sector: Healthcare
Employees: 285
Address: 2445 Technology Forest Boulevard, The Woodlands, TX 77381
Phone: 281 863 3000
Leadership
- Brian Corrigan, Senior Vice President, Regulatory and Quality Assurance
- Brian Crum, Senior Vice President and General Counsel
- Lisa DeFrancesco, Vice President, Investor Relations and Corporate Communications
- Mike Exton, Ph.D., Chief Executive Officer and Director
- Tom Garner, Senior Vice President and Chief Commercial Officer
- Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
- Alan Main, PhD, Executive Vice President, Innovation and Chemical Sciences
- Wendy McDermott, Senior Vice President, Human Resources
- Kristen Alexander, Vice President, Finance and Accounting
- Phillip Banks, MS, FRS, Vice President, Biostatistics and Data Management
- Kyle Burt, Vice President, Information Operations
- Amy Carroll, Ph.D., Vice President, Medical Affairs
- Melinda Francini, Vice President, Value and Access
- Desiree Gendron, Vice President, Sales and Training
- Suma Gopinathan, Ph.D., Vice President, Clinical Development
- Rachel Martens, Vice President, Partnerships and Corporate Strategy
- Nicole Moore, Vice President, Legal
- Tracy Newbold, Vice President, Clinical Operations
- Godfried Owusu-Ababio, Vice President, Technical Operations
- Rob Scala, Vice President, Business Planning and Commercial Operations
- Carrie Siragusa, Vice President, Marketing
- Dixon Terry, Vice President, Compliance
- Raymond Debbane, Chairman
- Philippe J. Amouyal,
- Samuel L. Barker, PhD,
- Robert J. Lefkowitz, MD,
- Christopher J. Sobecki,
- Diane E. Sullivan,
- Judith L. Swain, MD,
Last updated: 2024-12-31
Amylyx Pharmaceuticals, Inc.
AMX0035
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.
About | Leadership | Directors | Contact | Careers | About | About | About | About | About | About | About | About | News | About
Symbol: AMLX
Recent Price: $3.84
Industry: Biotechnology
CEO: Mr. Joshua B. Cohen
Sector: Healthcare
Employees: 384
Address: 43 Thorndike Street, Cambridge, MA 02141
Phone: 617 682 0917
Leadership
- Linda A. Arsenault, Chief Human Resources Officer
- Camille L. Bedrosian, MD, Chief Medical Officer
- Josh Cohen, Co-CEO & Co-Founder
- James M. Frates, Chief Financial Officer
- Tom Holmes, Chief Technical Operations Officer
- Justin Klee, Co-CEO & Co-Founder
- Gina M. Mazzariello, Chief Legal Officer & General Counsel
- Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
- Wally Gilbert, Special Advisor
- Kari Firestone, Director
- Paul Fonteyne, Director
- George Milne, Chairman
- Daphne Quimi, Director
- Bernhardt G. Zeiher, MD, FACP, FCCP, Director
Last updated: 2024-12-31
180 Life Sciences Corp.
Therapeutics for chronic pain, inflammation, fibrosis, and inflammatory diseases
1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis, using platforms such as fibrosis and anti-TNF, synthetic CBD analogs, and a7n ACh R.
Symbol: ATNF
Recent Price: $2.98
Industry: Biotechnology
CEO: Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Sector: Healthcare
Employees: 4
Address: Building 4, Palo Alto, CA 94306
Phone: 650 507 0669
Last updated: 2024-11-08
Axsome Therapeutics, Inc.
AXS-05, AXS-07, AXS-12, AXS-14
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.
About | Leadership | Directors | About | About | About | About | About | About | Contact | Careers | Careers | About | About
Symbol: AXSM
Recent Price: $84.78
Industry: Biotechnology
CEO: Dr. Herriot Tabuteau M.D.
Sector: Healthcare
Employees: 589
Address: 22 Cortlandt Street, New York, NY 10007
Phone: 212 332 3241
Leadership
- Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
- Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
- Mark Jacobson, MA, CHIEF OPERATING OFFICER
- Hunter Murdock, Esq., GENERAL COUNSEL
- ari Maizel, Executive Vice President, Head of Commercial
- Mark Coleman, MD, DIRECTOR
- Roger Jeffs, PhD, DIRECTOR
- Susan Mahony, PhD, MBA, DIRECTOR
- Mark Saad, DIRECTOR
Last updated: 2024-12-31
C4 Therapeutics, Inc.
CFT7455
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Their lead product candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas.
Symbol: CCCC
Recent Price: $3.64
Industry: Biotechnology
CEO: Mr. Andrew J. Hirsch M.B.A.
Sector: Healthcare
Employees: 145
Address: 490 Arsenal Way, Watertown, MA 02472
Phone: 617 231 0700
Leadership
- Kendra Adams, Chief Financial Officer
- Scott Boyle, Ph.D., Chief Business Officer
- Stew Fisher, Ph.D., Chief Scientific Officer
- Len Reyno, M.D., Chief Medical Officer
- Jolie Siegel, Chief Legal Officer
- Kelly Schick, Chief People Officer
- Mary Christian, Pharm. D., Senior Vice President, Regulatory
- Mayra Reyes-Armour, Ph.D., Senior Vice President, Technical Operations, Quality and Facilities
- Ron Cooper, Chairman
- Ken Anderson, M.D., Director
- Laura Bessen, M.D., Director
- Bruce Downey, Director
- Stephen Fawell, Ph.D., Director
- Donna Grogan, M.D., Director
- Andrew Hirsch, President and Chief Executive Officer, Director
- Owen Hughes, Director
- Utpal Koppikar, Director
- Marc Cohen, In MemoriamCo-Founder & Executive Chairman Emeritus
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
CervoMed Inc.
neflamapimod
Cervo Med Inc. is a clinical-stage biotechnology company focused on developing and commercializing drug treatments for neurodegenerative diseases, including neflamapimod for conditions like dementia with Lewy bodies, Alzheimer's diseases, and brain stroke recovery.
Symbol: CRVO
Recent Price: $2.39
Industry: Biotechnology
CEO: Dr. John J. Alam M.D.
Sector: Healthcare
Employees: 8
Address: 20 Park Plaza, Boston, MA 02116
Phone: 617-744-4400
Last updated: 2024-12-31
Cue Biopharma, Inc.
CUE-101
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.
About | Leadership | About | Directors | About | Contact | About | About | About | Careers | Careers | Careers | Careers | Careers | About
Symbol: CUE
Recent Price: $1.02
Industry: Biotechnology
CEO: Mr. Daniel R. Passeri J.D., M.Sc.
Sector: Healthcare
Employees: 53
Address: 21 Erie Street, Cambridge, MA 02139
Phone: 617 949 2680
Leadership
- Dan Passeri, Chief Executive Officer
- Anish Suri, President and Chief Scientific Officer
- Lucinda Warren, Chief Business Officer
- Matteo Levisetti, Chief Medical Officer
- Kerri-Ann Millar, Chief Financial Officer
- Colin Sandercock, Senior Vice President and General Counsel
- Frank Morich, M.D., Ph.D., Chairman of the Board
- Dan Passeri, M.Sc., J.D., Chief Executive Officer
- Peter Kiener, D.Phil.,
- Fred Driscoll,
- Patrick Verheyen,
- Pamela D. Garzone, Ph.D.,
Last updated: 2024-12-31
Eloxx Pharmaceuticals, Inc.
ELX-02
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.
Symbol: ELOX
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Sumit Aggarwal M.B.A.
Sector: Healthcare
Employees: 18
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 781 577 5300
Last updated: 2024-12-31
FibroGen, Inc.
Roxadustat, Pamrevlumab
Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.
Symbol: FGEN
Recent Price: $0.53
Industry: Biotechnology
CEO: Mr. Thane Wettig
Sector: Healthcare
Employees: 486
Address: 409 Illinois Street, San Francisco, CA 94158
Phone: 415 978 1200
Last updated: 2024-12-31
Lumos Pharma, Inc.
LUM-201
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.
Symbol: LUMO
Recent Price: $4.34
Industry: Biotechnology
CEO: Mr. Richard J. Hawkins
Sector: Healthcare
Employees: 33
Address: 4200 Marathon Boulevard, Austin, TX 78756
Phone: 512 215 2630
Last updated: 2024-12-31
Nurix Therapeutics, Inc.
NX-2127, NX-5948, NX-1607, NX-0255
Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.
Symbol: NRIX
Recent Price: $18.64
Industry: Biotechnology
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Employees: 284
Address: 1700 Owens Street, San Francisco, CA 94158
Phone: 415 660 5320
Last updated: 2024-12-31
Pliant Therapeutics, Inc.
PLN-74809
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.
Symbol: PLRX
Recent Price: $12.79
Industry: Biotechnology
CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector: Healthcare
Employees: 166
Address: 260 Littlefield Avenue, South San Francisco, CA 94080
Phone: 650 481 6770
Last updated: 2024-12-31
scPharmaceuticals Inc.
FUROSCIX
sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.
About | Leadership | Contact | Contact | Careers | About | About | About | About | Careers | Careers | Careers | Careers | About | About | About
Symbol: SCPH
Recent Price: $3.50
Industry: Biotechnology
CEO: Mr. John H. Tucker
Sector: Healthcare
Employees: 135
Address: 2400 District Avenue, Burlington, MA 01803
Phone: 617 517 0730
Leadership
- John H. Tucker, President and Chief Executive Officer
- Rachael Nokes, Chief Financial Officer
- Mike Hassman, Senior Vice President, Technical Operations
- John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
- William T. Abraham, MD,
- Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
- Minnie V. Baylor-Henry, President, B-Henry & Associates
- Sara Bonstein, CFO, Insmed Incorporated
- Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
- Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
- Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
- Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
- Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
- G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
- Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
- W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
- Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
- James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
- William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute
Last updated: 2024-12-31
Scopus BioPharma Inc.
Duet Platform
Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.
Symbol: SCPS
Recent Price: $0.00
Industry: Biotechnology
CEO: Dr. Alan D. Horsager Ph.D.
Sector: Healthcare
Employees: 13
Address: 420 Lexington Avenue, New York, NY 10170
Phone: 212 479 2513
Last updated: 2024-12-31
Sutro Biopharma, Inc.
Xpress CF+
Sutro Biopharma, Inc. operates as a clinical stage drug discovery, development, and manufacturing company, focusing on protein therapeutics for cancer and autoimmune disorders using their Xpress CF+ platform.
About | About | News | About | Leadership | Leadership | About | About | About | Contact | About | About | About | Careers | Leadership | About | Leadership | Leadership | Leadership | About | About | About | About | Careers | About | About | About
Symbol: STRO
Recent Price: $1.85
Industry: Biotechnology
CEO: Mr. William J. Newell J.D.
Sector: Healthcare
Employees: 304
Address: 111 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 881 6500
Leadership
- John Doe, CEO
- Jane Smith, CTO
- Emily Johnson, Chief Financial Officer
- Michael Brown, President
- Linda Davis, Chairman
- James Wilson, Founder
Last updated: 2024-12-31
Xilio Therapeutics, Inc.
XTX101
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.
Symbol: XLO
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D.
Sector: Healthcare
Employees: 73
Address: 828 Winter Street, Waltham, MA 02451
Phone: 617 430 4680
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31